Evogene (NASDAQ:EVGN) Director Leon Recanati Purchases 460,000 Shares

Evogene Ltd. (NASDAQ:EVGN) Director Leon Recanati purchased 460,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was bought at an average cost of $0.64 per share, for a total transaction of $294,400.00. Following the completion of the acquisition, the director directly owned 1,343,886 shares of the company’s stock, valued at $860,087.04. This represents a 52.04% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Evogene Price Performance

Shares of EVGN stock opened at $0.61 on Thursday. The firm has a market cap of $5.33 million, a P/E ratio of -0.44 and a beta of 1.40. Evogene Ltd. has a 1-year low of $0.37 and a 1-year high of $1.50. The firm has a fifty day moving average of $0.53 and a two-hundred day moving average of $0.73.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Saturday, May 16th. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33). The firm had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.35 million. Evogene had a negative return on equity of 158.82% and a negative net margin of 638.12%.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Evogene currently has an average rating of “Sell”.

Hedge Funds Weigh In On Evogene

Several institutional investors have recently modified their holdings of EVGN. XTX Topco Ltd acquired a new stake in shares of Evogene in the 4th quarter worth about $25,000. Jane Street Group LLC lifted its position in Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares during the last quarter. Finally, Citadel Advisors LLC boosted its stake in Evogene by 169.4% during the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 36,206 shares during the period. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.